In February, citing the need for more data, Pfizer and BioNTech announced that they were delaying the application for their COVID-19 vaccine for children under the age of 5. Earlier evidence suggests that two doses may not provide adequate protection in the 2- to 4-year old age group. With the larger number of infections and illness in the younger age group from the Omicron variant, Pfizer and BioNTech felt they needed more data on the effectiveness of a third dose.
Dr William Wilkoff
This delay came as a disappointment to parents of children under 5 who have been eager to have them receive the vaccination. However, Peter Marks, MD, director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, told parents that this delay should be reassuring — that the companies were doing important due diligence before releasing a product that is both safe and effective. The American Academy of Pediatrics wisely released a similar statement of reassurance and support.
It is difficult to know how many parents will eventually immunize their young children once the vaccine is approved. Any survey done more than a few weeks ago must be viewed cautiously as "the COVID numbers" around the country continue to improve and parental attitudes are likely to change.
Q&A: Meeting the Challenge of Giving COVID Vaccines to Younger Kids
FDA Committee to Discuss COVID-19 Shots for Kids in June
COMMENTARY
Waiting for the Under-5 COVID-19 Vaccine
William G. Wilkoff, MD
March 18, 2022
In February, citing the need for more data, Pfizer and BioNTech announced that they were delaying the application for their COVID-19 vaccine for children under the age of 5. Earlier evidence suggests that two doses may not provide adequate protection in the 2- to 4-year old age group. With the larger number of infections and illness in the younger age group from the Omicron variant, Pfizer and BioNTech felt they needed more data on the effectiveness of a third dose.
Dr William Wilkoff
This delay came as a disappointment to parents of children under 5 who have been eager to have them receive the vaccination. However, Peter Marks, MD, director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, told parents that this delay should be reassuring — that the companies were doing important due diligence before releasing a product that is both safe and effective. The American Academy of Pediatrics wisely released a similar statement of reassurance and support.
It is difficult to know how many parents will eventually immunize their young children once the vaccine is approved. Any survey done more than a few weeks ago must be viewed cautiously as "the COVID numbers" around the country continue to improve and parental attitudes are likely to change.
Credits:
Lead Image: Kyryl Gorlov/Dreamstime
Medscape Pediatrics © 2022 WebMD, LLC
Cite this: Waiting for the Under-5 COVID-19 Vaccine - Medscape - Mar 18, 2022.